Research showed that over 90% of pancreatic ductal adenocarcinoma (PDAC) cases harboured KRAS mutations, which activated PI3K/AKT signalling pathways, key drivers of tumour proliferation, drug resistance and metastasis34. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.